Dermatofibrosarcoma protuberans treated with wide local excision and followed at a cancer hospital: Prognostic significance of clinicopathologic variables

American Journal of Dermatopathology

Volumn 34, Issue 1, 2012, Pages 24-34

  Erdem, Ozlem ^a   Wyatt, Angela J ^b   Lin, E ^c   Wang, Xuemei ^c   Prieto, Victor G ^c  

^a GAZI UNIVERSITY   (Turkey)

^b Angela Wyatt Dermatology   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

dermatofibrosarcoma protuberans; follow up; recurrence; series

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOSURGERY; DERMATOFIBROSARCOMA PROTUBERANS; FEMALE; GENDER; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MITOSIS; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SKIN NECROSIS; TUMOR VOLUME; WIDE EXCISION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DERMATOFIBROSARCOMA; DISEASE-FREE SURVIVAL; FEMALE; FIBROSARCOMA; HUMANS; MALE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; TEXAS; YOUNG ADULT;

EID: 84856235797     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3182120671     Document Type: Article

References (23)

1. Billings SD, Folpe AL. Cutaneous and subcutaneous fibrohistiocytic tumors of intermediate malignancy. Am J Dermatopathol. 2004:26: 141-155. (Pubitemid 38429064)
2. Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous ("highgrade") dermatofibrosarcoma protuberans: clinicopathologic an immunohistochemical study of a series of 41 patients with emphasis on prognostic significance. Am J Surg Pathol. 1998;22;576-587. (Pubitemid 28213745)
3. Khatri VP, Galante JM, Bold RJ, et al. Dermatofibrosarcoma Protuberans: Reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol. 2003;10:1118-1122. (Pubitemid 40486838)
4. Pack GT, Tabah EF. Dermatofibrosarcoma protuberans: a report of thirtynine cases. Arch Surg. 1951;62:391-411.
5. Pedeutour F, Simon MP, Minoletti F, et al. Ring 22 chromosomes in dermatofibrosarcoma protuberans are low level amplifiers of chromosomes 17 and 22 sequences. Cancer Res. 1995;55:2400-2403.
6. Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the plateletderived growth factor b-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nature Genet. 1997;15:95-98. (Pubitemid 27014958)
7. Mark RJ, Bailet JW, Tran LM, et al. Dermatofibrosarcoma protuberans of head and neck. A report of 16 cases. Arch Otolaryngol Head Neck Surg. 1993;119:891-896. (Pubitemid 23232299)
8. DuBay D, Cimmino V, Lowe L, et al. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer. 2004;100:1008-1016. (Pubitemid 38222862)
9. Prieto VG, Reed JA, Shea CR. CD34 immunoreactivity distinguishes between scar tissue and residual tumor in re-excisional specimens of dermatofibrosarcoma protuberans. J Cutan Pathol. 1994;21:324-329. (Pubitemid 24280417)
10. Suit H, Spiro I, Mankin HJ, et al. Radiation in management of patients with dermatofibrosarcoma protuberans. J Clin Oncol. 1996;14: 2365-2369. (Pubitemid 26264889)
11. Rutkowski P, Van Glabbeke M, Rankin CJ, et al, European Organisation for Research and Treatment of Cancer Soft Tissue/Bone sarcoma Group, Southwest Oncology Group. Imatinib Mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772-1779.
12. Mendenhall WM, Zlotechi RA, Scarborough MJ. Dermatofibrosarcoma protuberans. Cancer. 2004;101:2503-2508. (Pubitemid 39532278)
13. Connelly JH, Evans HL. Dermatofibrosarcoma protuberans: a clinicopathologic review with emphasis on fibrosarcomatous areas. Am J Surg Pathol. 1992;16:921-925.
14. Vandeweyer E, De Saint Aubain Somerhausen N, Gebhart M. Dermatofibrosarcoma protuberans: How wide is wide in surgical excision? Acta Chir Belg. 2002;102:455-458.
15. Ivan D, Niveiro M, Diwan AH, et al. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol. 2006;33:280-285.
16. Abbott JJ, Oliveira AM, Nascimento AG. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol. 2006;30:436-443. (Pubitemid 43740143)
17. Bowne WB, Antonescu CR, Leung DHY, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88:2711-2720. (Pubitemid 30417931)
18. Ding J, Hashimoto H, Enjoji M. Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinicopathologic study of nine cases and a comparison of with allied tumors. Cancer. 1989;65:721-729. (Pubitemid 19185226)
19. Hisaoka M, Okamoto S, Morimitsu Y, et al. Dermatofibrosarcoma protuberans with fibrosarcomatous areas: molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Virchows Arch. 1998;433:323-329. (Pubitemid 28477033)
20. Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behaviour in eighteen cases treated by local excision with extended clinical follow-up. Am J Surg Pathol. 2000;20:1125-1130. (Pubitemid 30612834)
21. Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans: treated at a single institution: A surgical disease with a high cure rate. J Clin Oncol. 2005;23:7669-7675. (Pubitemid 46291832)
22. Parker TL, Zitelli JA. Surgical margins for excision of dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1995;32:233-236.
23. Gloster HM Jr, Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35:82-87. (Pubitemid 26231329)